Revvity, Inc. (NYSE:RVTY) posted third-quarter adjusted earnings on Monday that beat Wall Street estimates, prompting the company to upgrade its full-year earnings guidance while leaving its organic ...

CEO Prahlad Singh highlighted that Revvity achieved 6% organic growth in Q4 2024, with adjusted operating margins exceeding 30% and adjusted EPS reaching $1.42, surpassing expectations. These results ...

CEO Prahlad Singh stated that "we closed the year on a high note, with our fourth quarter revenue, organic growth and adjusted EPS, all surpassing our expectations. This strong fourth quarter ...

Revvity’s Signals platform, featuring ChemDraw, aims to drive significant growth. New products like Xynthetica and LabGistics are set to enhance AI capabilities. The company maintains a cautious ...

July 28 (Reuters) - Revvity (RVTY.N), opens new tab on Monday lowered its full-year adjusted profit forecast as it expects demand for diagnostics products in its key market China to be hurt by changes ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43 rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA.

Feb 2 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Prahlad Singh, CEO, Revvity: Yes. Luke Sergott, Analyst, Barclays: You have the logistics. Just walk through, like, what these updates are, what the launch time is, and how you guys think about this, ...

Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker's second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025. The ...